vs
AdvanSix Inc.（ASIX）与Axsome Therapeutics, Inc.（AXSM）财务数据对比。点击上方公司名可切换其他公司
AdvanSix Inc.的季度营收约是Axsome Therapeutics, Inc.的1.9倍（$359.9M vs $191.2M），Axsome Therapeutics, Inc.同比增速更快（57.4% vs 9.4%），过去两年Axsome Therapeutics, Inc.的营收复合增速更高（48.1% vs 3.4%）
AdvanSix Inc.是一家美国化工企业，主营尼龙6以及己内酰胺、硫酸铵肥料等相关化工产品。该公司原为霍尼韦尔旗下树脂与化工事业部，于2016年分拆独立，2019年预估营收达14亿美元，其企业历史可追溯至1884年在宾夕法尼亚州法兰克福成立的H. W. Jayne公司。
Jazz Pharmaceuticals是一家全球生物制药企业，专注于肿瘤学与神经科学领域的药物研发及商业化。公司2003年在美国加利福尼亚州成立，目前总部位于爱尔兰都柏林，业务覆盖全球多个核心市场。
ASIX vs AXSM — 直观对比
营收规模更大
ASIX
是对方的1.9倍
$191.2M
营收增速更快
AXSM
高出48.0%
9.4%
两年增速更快
AXSM
近两年复合增速
3.4%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $359.9M | $191.2M |
| 净利润 | $-2.8M | — |
| 毛利率 | 7.6% | — |
| 营业利润率 | -0.7% | -33.1% |
| 净利率 | -0.8% | — |
| 营收同比 | 9.4% | 57.4% |
| 净利润同比 | -892.9% | — |
| 每股收益（稀释后） | $-0.11 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASIXAXSM
| Q1 26 | — | $191.2M | ||
| Q4 25 | $359.9M | $196.0M | ||
| Q3 25 | $374.5M | $171.0M | ||
| Q2 25 | $410.0M | $150.0M | ||
| Q1 25 | $377.8M | $121.5M | ||
| Q4 24 | $329.1M | $118.8M | ||
| Q3 24 | $398.2M | $104.8M | ||
| Q2 24 | $453.5M | $87.2M |
净利润ASIXAXSM
| Q1 26 | — | — | ||
| Q4 25 | $-2.8M | $-28.6M | ||
| Q3 25 | $-2.6M | $-47.2M | ||
| Q2 25 | $31.4M | $-48.0M | ||
| Q1 25 | $23.3M | $-59.4M | ||
| Q4 24 | $352.0K | $-74.9M | ||
| Q3 24 | $22.3M | $-64.6M | ||
| Q2 24 | $38.9M | $-79.3M |
毛利率ASIXAXSM
| Q1 26 | — | — | ||
| Q4 25 | 7.6% | — | ||
| Q3 25 | 6.8% | — | ||
| Q2 25 | 14.3% | — | ||
| Q1 25 | 14.2% | — | ||
| Q4 24 | 3.4% | — | ||
| Q3 24 | 14.4% | — | ||
| Q2 24 | 17.9% | — |
营业利润率ASIXAXSM
| Q1 26 | — | -33.1% | ||
| Q4 25 | -0.7% | -13.8% | ||
| Q3 25 | -0.9% | -27.0% | ||
| Q2 25 | 7.7% | -24.5% | ||
| Q1 25 | 7.7% | -46.9% | ||
| Q4 24 | -3.9% | -61.1% | ||
| Q3 24 | 7.5% | -59.8% | ||
| Q2 24 | 11.5% | -89.5% |
净利率ASIXAXSM
| Q1 26 | — | — | ||
| Q4 25 | -0.8% | -14.6% | ||
| Q3 25 | -0.7% | -27.6% | ||
| Q2 25 | 7.7% | -32.0% | ||
| Q1 25 | 6.2% | -48.9% | ||
| Q4 24 | 0.1% | -63.1% | ||
| Q3 24 | 5.6% | -61.7% | ||
| Q2 24 | 8.6% | -91.0% |
每股收益（稀释后）ASIXAXSM
| Q1 26 | — | — | ||
| Q4 25 | $-0.11 | $-0.55 | ||
| Q3 25 | $-0.10 | $-0.94 | ||
| Q2 25 | $1.15 | $-0.97 | ||
| Q1 25 | $0.86 | $-1.22 | ||
| Q4 24 | $0.02 | $-1.54 | ||
| Q3 24 | $0.82 | $-1.34 | ||
| Q2 24 | $1.43 | $-1.67 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $19.8M | $305.1M |
| 总债务越低越好 | — | $70.0M |
| 股东权益账面价值 | $815.2M | — |
| 总资产 | $1.7B | $713.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASIXAXSM
| Q1 26 | — | $305.1M | ||
| Q4 25 | $19.8M | $322.9M | ||
| Q3 25 | $23.7M | $325.3M | ||
| Q2 25 | $18.4M | $303.0M | ||
| Q1 25 | $8.3M | $300.9M | ||
| Q4 24 | $19.6M | $315.4M | ||
| Q3 24 | $17.3M | $327.3M | ||
| Q2 24 | $12.1M | $315.7M |
总债务ASIXAXSM
| Q1 26 | — | $70.0M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益ASIXAXSM
| Q1 26 | — | — | ||
| Q4 25 | $815.2M | $88.3M | ||
| Q3 25 | $818.2M | $73.7M | ||
| Q2 25 | $823.7M | $73.1M | ||
| Q1 25 | $794.4M | $53.2M | ||
| Q4 24 | $774.6M | $57.0M | ||
| Q3 24 | $766.4M | $92.9M | ||
| Q2 24 | $746.6M | $102.9M |
总资产ASIXAXSM
| Q1 26 | — | $713.6M | ||
| Q4 25 | $1.7B | $689.8M | ||
| Q3 25 | $1.7B | $669.3M | ||
| Q2 25 | $1.6B | $639.8M | ||
| Q1 25 | $1.6B | $596.7M | ||
| Q4 24 | $1.6B | $568.5M | ||
| Q3 24 | $1.5B | $561.5M | ||
| Q2 24 | $1.5B | $548.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $63.7M | — |
| 自由现金流经营现金流 - 资本支出 | $36.1M | — |
| 自由现金流率自由现金流/营收 | 10.0% | — |
| 资本支出强度资本支出/营收 | 7.7% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $6.4M | — |
8季度趋势，按日历期对齐
经营现金流ASIXAXSM
| Q1 26 | — | — | ||
| Q4 25 | $63.7M | $-18.7M | ||
| Q3 25 | $26.6M | $1.0M | ||
| Q2 25 | $21.1M | $-32.4M | ||
| Q1 25 | $11.4M | $-43.4M | ||
| Q4 24 | $64.2M | $-26.2M | ||
| Q3 24 | $57.3M | $-18.6M | ||
| Q2 24 | $50.2M | $-30.1M |
自由现金流ASIXAXSM
| Q1 26 | — | — | ||
| Q4 25 | $36.1M | $-18.7M | ||
| Q3 25 | $66.0K | $988.0K | ||
| Q2 25 | $-7.2M | $-32.4M | ||
| Q1 25 | $-22.6M | $-43.7M | ||
| Q4 24 | $29.8M | $-26.2M | ||
| Q3 24 | $26.8M | $-18.7M | ||
| Q2 24 | $16.7M | $-30.2M |
自由现金流率ASIXAXSM
| Q1 26 | — | — | ||
| Q4 25 | 10.0% | -9.6% | ||
| Q3 25 | 0.0% | 0.6% | ||
| Q2 25 | -1.7% | -21.6% | ||
| Q1 25 | -6.0% | -36.0% | ||
| Q4 24 | 9.1% | -22.1% | ||
| Q3 24 | 6.7% | -17.9% | ||
| Q2 24 | 3.7% | -34.6% |
资本支出强度ASIXAXSM
| Q1 26 | — | — | ||
| Q4 25 | 7.7% | 0.0% | ||
| Q3 25 | 7.1% | 0.0% | ||
| Q2 25 | 6.9% | 0.0% | ||
| Q1 25 | 9.0% | 0.3% | ||
| Q4 24 | 10.4% | 0.0% | ||
| Q3 24 | 7.7% | 0.1% | ||
| Q2 24 | 7.4% | 0.1% |
现金转化率ASIXAXSM
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 182.29× | — | ||
| Q3 24 | 2.57× | — | ||
| Q2 24 | 1.29× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
